{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:02:43Z","timestamp":1773680563779,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN275201800001I"],"award-info":[{"award-number":["HHSN275201800001I"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tier 1 Canada Research Chair in Maternal-Child Health and HIV"},{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Integrase strand transfer inhibitors (INSTIs) are preferred for treatment of human immunodeficiency virus (HIV). However, safety data in pregnancy are limited for newer INSTIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pregnant C57BL\/6 mice were randomly allocated to control (water), dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC), or cabotegravir (CAB) at clinically relevant doses, administered orally with tenofovir disoproxil fumarate and emtricitabine, once daily from gestational day (GD) 0.5 to sacrifice (GD 15.5). Fetuses were assessed for gross anomalies. Descriptive statistics were used to compare proportions of gross anomalies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 550 litters (115 in the control group, 150 for DTG, 113 for RAL, 79 for BIC, and 93 for CAB) were assessed. RAL was associated with the highest fetal weight, placental weight, and fetal-placental weight ratio (placental efficiency). Fetal weight, placental efficiency, and litter size were lowest in BIC and CAB. Neural tube defects were observed only in INSTI groups, with litter prevalence rates of 0.66% for RAL, 0.45% for DTG, 0.39% for BIC, 0.15% for CAB, and 0% for the control. Tail defects, eye defects, bleeding defects, cranial swelling, and growth restriction were significantly more common in all INSTI groups than in the control group. Overall rates of defects were lowest with DTG. Compared with the DTG group, limb and tail defects (indicative of spinal dysraphism) were significantly more prevalent in the RAL group, while bleeding defects were significantly more prevalent in the BIC and CAB groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While INSTIs represent a critical advance in the management of HIV infection, the findings of the current study demonstrate a link between INSTI therapy and adverse fetal outcomes. This highlights the need for continued surveillance of pregnancy outcomes in women exposed to INSTIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf362","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:55:04Z","timestamp":1751615704000},"page":"847-858","source":"Crossref","is-referenced-by-count":2,"title":["Fetal Defects in Mice Treated With Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir, and Cabotegravir"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-8363","authenticated-orcid":false,"given":"Haneesha","family":"Mohan","sequence":"first","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Yee","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3405-0345","authenticated-orcid":false,"given":"Evelyn Yukino","family":"Laurette","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanvi","family":"Sanghvi","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-1372","authenticated-orcid":false,"given":"Oscar","family":"Tejada","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6040","authenticated-orcid":false,"given":"Jennifer","family":"Jao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-283X","authenticated-orcid":false,"given":"John G","family":"Sled","sequence":"additional","affiliation":[{"name":"Translational Medicine, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]},{"name":"Mouse Imaging Center, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medical Biophysics, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-5248","authenticated-orcid":false,"given":"Nicholas D E","family":"Greene","sequence":"additional","affiliation":[{"name":"Developmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-9117","authenticated-orcid":false,"given":"Andrew J","family":"Copp","sequence":"additional","affiliation":[{"name":"Developmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-6134","authenticated-orcid":false,"given":"Lena","family":"Serghides","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Immunology and Institute of Medical Sciences, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025101515143188100_jiaf362-B1","volume-title":"Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States","author":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission"},{"key":"2025101515143188100_jiaf362-B2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101515143188100_jiaf362-B3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"key":"2025101515143188100_jiaf362-B4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0000000000004745","article-title":"Birth defects and adverse pregnancy outcomes in hospital-based birth surveillance in Eswatini","volume":"44","author":"Gill","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2025101515143188100_jiaf362-B5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/QAI.0000000000002597","article-title":"Enhanced and timely investigation of ARVs for use in pregnant women","volume":"86","author":"Abrams","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025101515143188100_jiaf362-B6","doi-asserted-by":"crossref","first-page":"e0276473","DOI":"10.1371\/journal.pone.0276473","article-title":"Congenital malformations and preeclampsia associated with integrase inhibitor use in pregnancy: a single-center analysis","volume":"18","author":"Smith","year":"2023","journal-title":"PLoS One"},{"key":"2025101515143188100_jiaf362-B7","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1093\/cid\/ciac703","article-title":"Update of perinatal human immunodeficiency virus type 1 transmission in France: zero transmission for 5482 mothers on continuous antiretroviral therapy from conception and with undetectable viral load at delivery","volume":"76","author":"Sibiude","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025101515143188100_jiaf362-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/QAD.0000000000004041","article-title":"Birth outcomes following bictegravir exposure during pregnancy","volume":"39","author":"Olivero","year":"2024","journal-title":"AIDS"},{"key":"2025101515143188100_jiaf362-B9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAI.0000000000001924","article-title":"Brief report: surveillance of congenital anomalies after exposure to raltegravir or elvitegravir during pregnancy in the United Kingdom and Ireland, 2008\u20132018","volume":"80","author":"Rasi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025101515143188100_jiaf362-B10","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(23)00108-X","article-title":"Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008\u201320: a national cohort study","volume":"10","author":"Kourtis","year":"2023","journal-title":"Lancet HIV"},{"key":"2025101515143188100_jiaf362-B11","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/QAD.0000000000003955","article-title":"First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort","volume":"38","author":"Fung","year":"2024","journal-title":"AIDS"},{"key":"2025101515143188100_jiaf362-B12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/1471-0528.15838","article-title":"Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study","volume":"126","author":"Money","year":"2019","journal-title":"BJOG"},{"key":"2025101515143188100_jiaf362-B13","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","article-title":"Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study","volume":"8","author":"Pereira","year":"2021","journal-title":"Lancet HIV"},{"key":"2025101515143188100_jiaf362-B14","doi-asserted-by":"crossref","first-page":"e5801","DOI":"10.1002\/pds.5801","article-title":"The antiretroviral pregnancy registry: three decades of prospective monitoring for birth defects","volume":"33","author":"Albano","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101515143188100_jiaf362-B15","doi-asserted-by":"crossref","first-page":"e26401","DOI":"10.1002\/jia2.26401","article-title":"Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and Southern Africa: a secondary analysis of HPTN 084","volume":"28","author":"Delany-Moretlwe","year":"2025","journal-title":"J Int AIDS Soc"},{"key":"2025101515143188100_jiaf362-B16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hiv.13439","article-title":"Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials","volume":"24","author":"Patel","year":"2023","journal-title":"HIV Med"},{"key":"2025101515143188100_jiaf362-B17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yrtph.2012.03.009","article-title":"Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches: a workshop report","volume":"63","author":"van der Laan","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025101515143188100_jiaf362-B18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdr2.1635","article-title":"Absence of developmental and reproductive toxicity in animals exposed to dolutegravir","volume":"112","author":"Stanislaus","year":"2020","journal-title":"Birth Defects Res"},{"key":"2025101515143188100_jiaf362-B19","author":"Food and Drug Administration"},{"key":"2025101515143188100_jiaf362-B20","author":"Food and Drug Administration"},{"key":"2025101515143188100_jiaf362-B21","author":"Food and Drug Administration"},{"key":"2025101515143188100_jiaf362-B22","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/QAD.0000000000002289","article-title":"The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid","volume":"33","author":"Cabrera","year":"2019","journal-title":"AIDS"},{"key":"2025101515143188100_jiaf362-B23","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.3390\/ijms25094640","article-title":"Dolutegravir and folic acid interaction during neural system development in zebrafish embryos","volume":"25","author":"Zizioli","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025101515143188100_jiaf362-B24","doi-asserted-by":"crossref","first-page":"103167","DOI":"10.1016\/j.ebiom.2020.103167","article-title":"Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels","volume":"63","author":"Mohan","year":"2021","journal-title":"EBioMedicine"},{"key":"2025101515143188100_jiaf362-B25","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.ebiom.2023.104762","article-title":"Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model","volume":"95","author":"Mohan","year":"2023","journal-title":"EBioMedicine"},{"key":"2025101515143188100_jiaf362-B26","doi-asserted-by":"crossref","first-page":"1175917","DOI":"10.3389\/fcell.2023.1175917","article-title":"Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir","volume":"11","author":"Gelineau-van Waes","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2025101515143188100_jiaf362-B27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAD.0000000000003639","article-title":"Dolutegravir-induced neural tube defects in mice are folate responsive","volume":"38","author":"Tukeman","year":"2024","journal-title":"AIDS"},{"key":"2025101515143188100_jiaf362-B28","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/infdis\/jiac386","article-title":"Second-generation human immunodeficiency virus integrase inhibitors induce differentiation dysregulation and exert toxic effects in human embryonic stem cell and mouse models","volume":"226","author":"Smith","year":"2022","journal-title":"J Infect Dis"},{"key":"2025101515143188100_jiaf362-B29","doi-asserted-by":"crossref","first-page":"e12418","DOI":"10.1371\/journal.pone.0012418","article-title":"Mouse gestation length is genetically determined","volume":"5","author":"Murray","year":"2010","journal-title":"PLoS One"},{"key":"2025101515143188100_jiaf362-B30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2018.09.008","article-title":"Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens","volume":"159","author":"Kala","year":"2018","journal-title":"Antiviral Res"},{"key":"2025101515143188100_jiaf362-B31","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/pharmaceutics14091761","article-title":"A pharmacokinetic dose-optimization study of cabotegravir and bictegravir in a mouse pregnancy model","volume":"14","author":"Mohan","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025101515143188100_jiaf362-B32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrg1181","article-title":"The genetic basis of mammalian neurulation","volume":"4","author":"Copp","year":"2003","journal-title":"Nat Rev Genet"},{"key":"2025101515143188100_jiaf362-B33","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198503682.001.0001","volume-title":"Theory of probability","author":"Jeffreys","year":"1998"},{"key":"2025101515143188100_jiaf362-B34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2025101515143188100_jiaf362-B35","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.molmet.2023.101707","article-title":"The long-lasting shadow of litter size in rodents: litter size is an underreported variable that strongly determines adult physiology","volume":"71","author":"Parra-Vargas","year":"2023","journal-title":"Mol Metab"},{"key":"2025101515143188100_jiaf362-B36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphys.2016.00028","article-title":"Placental adaptation: what can we learn from birthweight:placental weight ratio?","volume":"7","author":"Hayward","year":"2016","journal-title":"Front Physiol"},{"issue":"Suppl 3","key":"2025101515143188100_jiaf362-B37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1528-1157.44.s3.5.x","article-title":"Pathobiology and genetics of neural tube defects","volume":"44","author":"Finnell","year":"2003","journal-title":"Epilepsia"},{"key":"2025101515143188100_jiaf362-B38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/QAI.0000000000002031","article-title":"Evaluation of neural tube defects (NTDs) after exposure to raltegravir during pregnancy","volume":"81","author":"Shamsuddin","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025101515143188100_jiaf362-B39","first-page":"2747","article-title":"Imaging spectrum of spinal dysraphism: a diagnostic challenge","volume":"27","author":"Shrivastva","year":"2023","journal-title":"SA J Radiol"},{"key":"2025101515143188100_jiaf362-B40","doi-asserted-by":"crossref","first-page":"e1247","DOI":"10.1002\/prp2.1247","article-title":"Integrase inhibitor drugs during pregnancy and congenital anomalies: a case\/non-case study from the global pharmacovigilance database VigiBase\u00ae","volume":"12","author":"Saint-Lary","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"2025101515143188100_jiaf362-B41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrm3598","article-title":"The mechanisms of hedgehog signalling and its roles in development and disease","volume":"14","author":"Briscoe","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025101515143188100_jiaf362-B42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1242\/dev.065938","article-title":"Retinoic acid signalling during development","volume":"139","author":"Rhinn","year":"2012","journal-title":"Development"},{"key":"2025101515143188100_jiaf362-B43","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3390\/ijms20092275","article-title":"Sonic hedgehog signaling is required for Cyp26 expression during embryonic development","volume":"20","author":"El Shahawy","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025101515143188100_jiaf362-B44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1124\/dmd.119.087635","article-title":"Clinical extrapolation of the effects of dolutegravir and other HIV integrase inhibitors on folate transport pathways","volume":"47","author":"Zamek-Gliszczynski","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2025101515143188100_jiaf362-B45","doi-asserted-by":"crossref","first-page":"1113032","DOI":"10.3389\/ftox.2023.1113032","article-title":"Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors","volume":"5","author":"Foster","year":"2023","journal-title":"Front Toxicol"},{"key":"2025101515143188100_jiaf362-B46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.isci.2019.05.027","article-title":"Degradation of extracellular matrix by matrix metalloproteinase 2 is essential for the establishment of the blood-brain barrier in Drosophila","volume":"16","author":"Kanda","year":"2019","journal-title":"iScience"},{"key":"2025101515143188100_jiaf362-B47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Page-McCaw","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025101515143188100_jiaf362-B48","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1074\/jbc.M113.517904","article-title":"Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot","volume":"289","author":"Nikolajsen","year":"2014","journal-title":"J Biol Chem"},{"key":"2025101515143188100_jiaf362-B49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrendo.2016.37","article-title":"Micronutrient deficiencies in pregnancy worldwide: health effects and prevention","volume":"12","author":"Gernand","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2025101515143188100_jiaf362-B50","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1080\/14767058.2020.1860930","article-title":"Maternal serum zinc concentration and neural tube defects in offspring: a meta-analysis","volume":"35","author":"Cheng","year":"2022","journal-title":"J Matern Fetal Neonatal Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf362\/63724671\/jiaf362.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/4\/847\/63724671\/jiaf362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/4\/847\/63724671\/jiaf362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:16:48Z","timestamp":1760555808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/4\/847\/8196267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf362","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,7,15]]}}}